Biedrba "Apvienba HIV.LV" (ik dienu pl. 9 - 21)
apvieniba@apvienibahiv.lv

 
   
107922

C hepatta rstana brniem no trs gadu vecuma
Apskatt komentrus (0)


10.09.2019


ASV Prtikas produktu un zu kontroles prvalde (FDA) apstiprinjusi, ka brnus no trs gadu vecuma var rstt no hronisk C hepatta, izmantojot sofosbuvru un sofosbuvra / ledipasvra kombinciju. Ldz im vecuma cenzs bija 12 gadu. Uzskot rstanu brna agrn vecum, iespjams novrst nopietnu aknas bojjumu raanos. 
Pateicoties brna agrnai rstanai, tiks novrsta nopietnu aknas bojjumu veidoans. FDA rekomendcijai jkst par pamatu, lai prskattu C hepatta rstanas brniem starptautiskos protokolus, nordts ziojum.
Brniem, kuri slimo ar C hepatta 2. vai 3. genotipu, visos gadjumos un neatkargi no iepriekjs rstanas tiek rekomendts rstanai izmantot sofosbuvru kombincij ar ribavirnu. rstanai jilgst 12 vai 24 nedas. Lai brniem rsttu C hepatta 1., 4., 5., 6. genotipu bez aknu cirozes vai ar kompensto cirozi, ieteicams izmantot sofosbuvru / ledipasvru. rstanai jilgst 12 vai 24 nedas, ja ir bijusi iepriekjas rstanas pieredze. 
***********************
Source: Healio | FDA approves label changes for Sovaldi, Harvoni in children with HCV | https://www.healio.com/hepatology/hepatitis-c/news/online/%7B5edae8d8-c4f3-4334-8883-7cc06a04c750%7D/fda-approves-label-changes-for-sovaldi-harvoni-in-children-with-hcv |
The FDA approved changes to the labeling of direct-acting antivirals Sovaldi and Harvoni to include information on dosage and administration in pediatric patients with hepatitis C aged 3 years to younger than 12 years.
Sovaldi (sofosbuvir, Gilead Sciences) is indicated for the treatment of chronic HCV genotype 2 or genotype 3 in patients aged 3 years or older without cirrhosis or with compensated cirrhosis regardless of treatment experience.
Sofosbuvir should be administered with ribavirin for 12 weeks in patients with genotype 2 and for 24 weeks in those with genotype 3. The DAA can be administered as tablets or oral pellets with or without food based on the patients weight.
Adverse events to sofosbuvir with ribavirin were consistent with those observed in clinical studies of adult patients. Decreased appetite occurred in 13% of patients.
Harvoni (sofosbuvir/ledipasvir, Gilead Sciences) is indicated for the treatment of chronic HCV in pediatric patients aged 3 years and older with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis; in those with genotype 1 with decompensated cirrhosis; and with combination ribavirin in liver transplant recipients with genotype 1 or 4 without cirrhosis or with compensated cirrhosis.
Administration of sofosbuvir/ledipasvir should continue for 12 weeks in most patients and for 24 weeks in treatment-experienced patients with compensated cirrhosis. Patients can receive either tablets or oral pellets.
Adverse events to sofosbuvir/ledipasvir were also consistent with those observed in adults with no grade 3 or grade 4 adverse reactions or discontinuation due to adverse events.




 
      Atpaka

atstj tuku: atstj tuku:
vrds:




Ievadiet drobas kodu:

Visual CAPTCHA